PErsonalized TReatment for Endometrial Carcinoma
Launched by UNIVERSITY OF HELSINKI · Dec 8, 2022
Trial Information
Current as of February 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at different treatment options for women with early-stage endometrial cancer, specifically types that are considered high-risk for recurrence. The researchers want to see how well two main types of treatment work: one group of participants will receive chemotherapy, while another group will get a combination of chemotherapy and radiation. Additionally, they will compare two types of radiation therapy—vaginal brachytherapy and whole pelvic radiotherapy—based on specific cancer characteristics.
To be eligible for this trial, participants should be women aged 18 to 100 who have been diagnosed with stage I or II high-risk endometrial cancer. They should have a good overall health status and should not have had certain previous cancers or treatments that could interfere with the study. If you decide to participate, you’ll be closely monitored throughout the process and will contribute to important research that could help improve treatment for future patients with similar conditions.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age 18 to 100 years
- • WHO performance status 0 to 2
- • Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma
- Exclusion Criteria:
- • Age \<18 years or \>100 years
- • WHO performance status \>2
- • Uterine sarcoma
- • A history of malignancy within 5 years
- • Previous pelvic radiotherapy
- • An interval of \>30 days between surgery and start of chemotherapy or \>8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval)
Trial Officials
Mikko Loukovaara
Principal Investigator
Helsinki University Central Hospital
About University Of Helsinki
The University of Helsinki, a prestigious institution in Finland, is dedicated to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university engages in cutting-edge studies that aim to improve patient outcomes and contribute to the global knowledge base in medicine. Its commitment to ethical standards and rigorous methodology ensures the integrity and reliability of its clinical research initiatives, making it a key player in the development of novel therapeutic strategies and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials